(Liver Cancer) Is Tecentriq + Avastin Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On October 21, 2019, Roche announced the efficacy and safety results from the IMbrave150 Phase III clinical trial evaluating the anti-PD-L1 antibody Tecentriq (atezolizumab) + Avastin (bevacizumab) in previously untreated, unresectable hepatocellular carcinoma (HCC) patients.
The IMbrave150 Phase III trial was a multicenter international open-label study. Previously untreated, unresectable HCC patients (N=501) were randomized in a 2:1 ratio to the following two groups:
- Tecentriq + Avastin group: Tecentriq 1200 mg + Avastin 15 mg/kg on Day 1 of each 21-day cycle
- Sorafenib (Nexavar) 400 mg monotherapy group
Results for the primary endpoints — overall survival (OS) and progression-free survival (PFS) — both demonstrated improvements in the Tecentriq + Avastin group. Detailed trial results are to be presented at a future academic conference. In terms of safety, the adverse events observed with Tecentriq in this trial were consistent with the profiles confirmed in other ongoing clinical trials, with no new adverse events identified.
Based on the IMbrave150 trial results, Levi Garraway issued the following conclusion: For previously untreated, unresectable HCC patients — where sorafenib monotherapy is the current standard of care — Tecentriq + Avastin demonstrated improved overall survival, which is a reason for optimism.
Source: https://www.roche.com/media/releases/med-cor-2019-10-21.htm
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2